Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
2 clusters · 4 sources · 5 days · First seen · Last updated
Advancements in blood-based colorectal cancer detection
Overview
Recent clinical data and research highlight advancements in blood-based screening methods for colorectal cancer (CRC).
Clinical updates regarding the SimpleScreen CRC test show improved sensitivity for detecting advanced precancerous lesions, rising from 13.7% to 18.2%, while maintaining an 80.4% sensitivity for colorectal cancer. Additionally, modeling of Guardant Health’s Shield test suggests that blood-based screening may be more effective than traditional stool-based methods at increasing follow-up colonoscopies and averting deaths.
Parallel research into protein biomarkers has identified specific signatures capable of distinguishing advanced neoplasia. Studies involving the Olink platform, including the DIOPTRA project, demonstrated that a 12-protein signature achieved 98.1% sensitivity for CRC detection, with a 17-protein signature maintaining 94.4% sensitivity for Stage I disease. Further findings indicate that protein differences vary between colon and rectal cancers, suggesting a need for site-specific diagnostic signatures.
Entities
Freenome · American College of Gastroenterology · Horizon Europe · DIOPTRA project · Olink
Timeline
-
[HEALTH] 2 sourcesBlood-based protein biomarkers show promise for early colorectal cancer detection
New research identifies blood-based protein signatures that can detect colorectal cancer with high sensitivity, potentially offering a minimally invasive alternative for early-stage screening.
-
[HEALTH] 2 sourcesBlood-based colorectal cancer tests show improved detection and survival rates
New research presented at the ACG 2026 meeting shows blood-based colorectal cancer tests, including Freenome’s SimpleScreen CRC and Guardant Health’s Shield, may improve lesion detection and survival rates.
Sources
clpmag.com · emjreviews.com · fightcolorectalcancer.org · mdmag.com